MX2009009701A - Novel prophylactic and/or therapeutic agent for diabetic neuropathy. - Google Patents
Novel prophylactic and/or therapeutic agent for diabetic neuropathy.Info
- Publication number
- MX2009009701A MX2009009701A MX2009009701A MX2009009701A MX2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetic
- therapeutic agent
- prophylactic
- nerve disorder
- abnormal
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 230000000069 prophylactic effect Effects 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000002159 abnormal effect Effects 0.000 abstract 3
- 210000005036 nerve Anatomy 0.000 abstract 3
- 208000004044 Hypesthesia Diseases 0.000 abstract 2
- 230000003387 muscular Effects 0.000 abstract 2
- -1 2-[(substituted-indene-7-yloxy)methyl]morpholine Chemical class 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 abstract 1
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010031127 Orthostatic hypotension Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010053552 allodynia Diseases 0.000 abstract 1
- 210000000467 autonomic pathway Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 208000013046 dyshidrosis Diseases 0.000 abstract 1
- 230000026781 habituation Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 231100000862 numbness Toxicity 0.000 abstract 1
- 201000011414 pompholyx Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Disclosed is an excellent prophylactic and/or therapeutic agent for diabetic neuropathy, which comprises a 2-[(substituted-indene-7-yloxy)methyl]morpholine represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The prophylactic and/or therapeutic agent is particularly useful as a prophylactic and/or therapeutic agent for diabetic motor nerve disorder (e.g., decrease in muscular strength (decrease in muscular strength to an extent of being unable to independently walk)), diabetic sensory nerve disorder (paresthetic (abnormal vibratory sensation), allodynia, reduced sensation (numbness in limbs, psychroesthesia) or pain), or diabetic autonomic nerve disorder (e.g., abnormal bowel habituation such as constipation and diarrhea, urinary dysfunction, impotence, orthostatic hypotension, dyshidrosis, abnormal heart rate variability, delayed gastric emptying). Also disclosed is an ameliorating gent for a disease condition of diabetic nerve disorder.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007066727 | 2007-03-15 | ||
| JP2007242210 | 2007-09-19 | ||
| PCT/JP2008/054710 WO2008111669A1 (en) | 2007-03-15 | 2008-03-14 | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009701A true MX2009009701A (en) | 2009-10-07 |
Family
ID=39759597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009701A MX2009009701A (en) | 2007-03-15 | 2008-03-14 | Novel prophylactic and/or therapeutic agent for diabetic neuropathy. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100113451A1 (en) |
| EP (1) | EP2123643A4 (en) |
| JP (1) | JP5278308B2 (en) |
| KR (1) | KR20090130052A (en) |
| AU (1) | AU2008225379A1 (en) |
| BR (1) | BRPI0808806A2 (en) |
| CA (1) | CA2680938A1 (en) |
| IL (1) | IL200669A0 (en) |
| MX (1) | MX2009009701A (en) |
| RU (1) | RU2465906C2 (en) |
| TW (1) | TW200846003A (en) |
| WO (1) | WO2008111669A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428181C1 (en) * | 2010-05-25 | 2011-09-10 | Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. И.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" | Method of reducing level of glycemia and insulin-resistance in patients with type 2 diabetes mellitus |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102149386A (en) * | 2008-09-11 | 2011-08-10 | 安斯泰来制药株式会社 | Novel pharmaceutical composition for treating nociceptive pain |
| JPWO2010029959A1 (en) * | 2008-09-11 | 2012-02-02 | アステラス製薬株式会社 | New salts of morpholine derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4109088A (en) * | 1975-01-29 | 1978-08-22 | Yamanouchi Pharmaceutical Co., Ltd. | 2-(indenyloxymethyl) morpholine derivatives |
| JPS52111580A (en) * | 1976-03-15 | 1977-09-19 | Yamanouchi Pharmaceut Co Ltd | Novel indene derivatives and salts thereof |
| WO1994018182A1 (en) * | 1993-02-10 | 1994-08-18 | Yamanouchi Pharmaceutical Co., Ltd. | Morpholine derivative |
| WO2000015223A1 (en) * | 1998-09-15 | 2000-03-23 | Eli Lilly And Company | Treatment of persistent pain |
| US6380200B1 (en) * | 1999-12-07 | 2002-04-30 | Pfizer, Inc. | Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| BRPI0510453A (en) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | Substituted Morpholine Compounds for the Treatment of Central Nervous System Disorders |
| WO2006006617A1 (en) * | 2004-07-14 | 2006-01-19 | Astellas Pharma Inc. | Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| US7919510B2 (en) * | 2005-05-18 | 2011-04-05 | Neuraxon, Inc | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity |
| ATE530175T1 (en) * | 2006-06-08 | 2011-11-15 | Ucb Pharma Gmbh | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS |
-
2008
- 2008-03-13 TW TW097108876A patent/TW200846003A/en unknown
- 2008-03-14 EP EP08722106A patent/EP2123643A4/en not_active Withdrawn
- 2008-03-14 CA CA002680938A patent/CA2680938A1/en not_active Abandoned
- 2008-03-14 KR KR1020097021416A patent/KR20090130052A/en not_active Withdrawn
- 2008-03-14 RU RU2009138032/15A patent/RU2465906C2/en not_active IP Right Cessation
- 2008-03-14 WO PCT/JP2008/054710 patent/WO2008111669A1/en not_active Ceased
- 2008-03-14 US US12/530,745 patent/US20100113451A1/en not_active Abandoned
- 2008-03-14 AU AU2008225379A patent/AU2008225379A1/en not_active Abandoned
- 2008-03-14 BR BRPI0808806-3A patent/BRPI0808806A2/en not_active IP Right Cessation
- 2008-03-14 JP JP2009504092A patent/JP5278308B2/en not_active Expired - Fee Related
- 2008-03-14 MX MX2009009701A patent/MX2009009701A/en not_active Application Discontinuation
-
2009
- 2009-09-01 IL IL200669A patent/IL200669A0/en unknown
-
2012
- 2012-08-23 US US13/592,544 patent/US20130023535A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428181C1 (en) * | 2010-05-25 | 2011-09-10 | Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. И.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" | Method of reducing level of glycemia and insulin-resistance in patients with type 2 diabetes mellitus |
Also Published As
| Publication number | Publication date |
|---|---|
| IL200669A0 (en) | 2010-05-17 |
| KR20090130052A (en) | 2009-12-17 |
| RU2465906C2 (en) | 2012-11-10 |
| EP2123643A4 (en) | 2011-12-07 |
| JPWO2008111669A1 (en) | 2010-06-24 |
| RU2009138032A (en) | 2011-04-20 |
| US20130023535A1 (en) | 2013-01-24 |
| US20100113451A1 (en) | 2010-05-06 |
| CA2680938A1 (en) | 2008-09-18 |
| TW200846003A (en) | 2008-12-01 |
| JP5278308B2 (en) | 2013-09-04 |
| AU2008225379A1 (en) | 2008-09-18 |
| EP2123643A1 (en) | 2009-11-25 |
| BRPI0808806A2 (en) | 2014-08-19 |
| WO2008111669A1 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012005500A3 (en) | Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| WO2005116002A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| SG153830A1 (en) | Galenic formulations of organic compounds | |
| FR12C0052I1 (en) | ||
| WO2014146082A1 (en) | Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve | |
| MX342007B (en) | Drug conjugate composition. | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| WO2006124447A3 (en) | Substituted n-arylpyrrolidines as selective androgen receptor modulators | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| MX2008013827A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders. | |
| HRP20140280T1 (en) | Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain | |
| WO2004087048A3 (en) | Benzamide modulators of metabotropic glutamate receptors | |
| MX2009009701A (en) | Novel prophylactic and/or therapeutic agent for diabetic neuropathy. | |
| WO2008060332A3 (en) | Methods for treating or reducing muscle fatigue | |
| MX2012001160A (en) | Sphingosine-1-phosphate receptor agonists. | |
| MX347237B (en) | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction. | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| CA2262268C (en) | Method of treating impotence due to spinal cord injury | |
| NZ595798A (en) | Ectoparasiticidal methods and formulations | |
| WO2010022326A3 (en) | Transdermal delivery of apomorphine using microneedles | |
| EA200801310A1 (en) | PHARMACEUTICAL PREPARATIONS AND THEIR APPLICATION IN THE TREATMENT OF SEXUAL DYSFUNCTION IN WOMEN | |
| WO2007139433A8 (en) | Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application | |
| RU2009145804A (en) | AXOMADOL FOR TREATING PAIN FROM ARTHROSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |